TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: QRS duration as a predictor of overall mortality
Endpoint domain: Mortality/survival
Primary endpoint: Haematopoietic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hb levels maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in knowledge of diabetic foot care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in self-care scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in prevalence of callosities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: T cell functionality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of correct answers in Stroop Test (congruent situation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Latency in Stroop Test (incongruent situation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Daily salt intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24HUNa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean decrease in CRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: highest level of sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in technical skills performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in response times for technical tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in comprehensive behavioral scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Nitric oxide synthase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total nitrite levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ROP knowledge improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic ability improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AIMS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of cardiovascular disease or myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: High-sensitivity C-reactive protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximal CIMT regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of venous thromboembolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: change in volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical cure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate cancer cases identified
Endpoint domain: Mortality/survival
Primary endpoint: Gleason 7 or higher grade cancers identified
Endpoint domain: Mortality/survival
Primary endpoint: QTcF prolongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: IACT duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: improved glycaemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: increased autonomy support perceived from health professionals
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: increased perceived competence in managing diabetes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: reduced or cleared sputum bacterial load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: significant improvement in chest radiographs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pubertal duration after stop of GnRHa treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height gain from onset of puberty until AH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FINS levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: InHOMA-IR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Identification of medications by name
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Confusion due to look-alike tablets or pills
Endpoint domain: Adverse events/effects
Primary endpoint: loco-regional control (LRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating glypican‐4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy and fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Maximal ADP-induced platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: P2Y12 Reaction Units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: fragmentation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to fragmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cured at the end of therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Helkimo Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF‐36 Health Survey ‐ subscale 'Bodily Pain'
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of severe RDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: vertebral artery diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: mean velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: blood flow per minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percentage of patients whose diagnosis failed or could not be reached
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of medical and nursing staff satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Average number of days to reach a proper diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Classification of cancer versus healthy mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Classification of lesions versus healthy mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Classification of benign and (pre‐)malignant lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in mean scores for T cells and adhesion molecules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adalimumab long-term maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety level (STAI score)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: hospitalisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prognostic value of biomarkers (S‐100B and NSE) for clinical outcome
Endpoint domain: Mortality/survival
Primary endpoint: Sustained viral response
Endpoint domain: Mortality/survival
Primary endpoint: Health-related quality of life (HRQOL) in vitality domain
Endpoint domain: Life impact
Endpoint subdomain: Vitality
Primary endpoint: Health-related quality of life (HRQOL) in role-emotional domain
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Health-related quality of life (HRQOL) in social functioning domain
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: 2,3-dinor-6-keto-PGF(1alpha)/11-dehydro-TxB(2) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of corneal neovascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: LDL-C plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total-cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: circulating LCP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in anticipated patient falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of HIF-1α
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of VEGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impairment of drug-related memory reconsolidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Hct
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate in the i.v. group
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Obtaining a mammogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Obtaining a Pap test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Average time-to-service
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Respiratory index 3 hours after CPB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Body weight percent ratio 24 and 48 hours after CPB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scapular upward rotation deficits postfatigue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: postoperative fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: levels of pre-albumin, CD3, CD4, CD4/CD8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: levels of albumin and IgA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: rate of major clinical events
Endpoint domain: Mortality/survival
Primary endpoint: donor site pain incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Concentration of proinflammatory cytokine interleukin‐6 (IL‐6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of leukocytes in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of epidural venous puncture
Endpoint domain: Adverse events/effects
Primary endpoint: microbiological effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pain Reduction Score (PRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall rate of exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: use of as-needed reliever medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total and bioavailable testosterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Behavior changes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cardiac diastolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: OHIP-EDENT-J scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total Testosterone (TT) average
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Free Testosterone (fT) average
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Marginal bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: CIMT regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postprandial glucose peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 5-year survival estimate
Endpoint domain: Mortality/survival
Primary endpoint: LA longitudinal diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LA surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: composed knot score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median knotting time per completed knot
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of completed knots
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of 'dipstick' proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pelvic pain resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid profile stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Laboratory changes
Endpoint domain: Adverse events/effects
Primary endpoint: Need for i.v. lines
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Coefficient of variation of arterial oxygen tension (PaO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ipsilateral quadriceps strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ipsilateral pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in sleepiness
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Onset of non-communicable risk factors and disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBV DNA log10 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of HBV DNA more than 10(5) copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant retention for one year
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Reporting of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean reduction in average numerical rating scale pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCSK9 concentration reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Achievement of more than 900 kcal/week of exercise-based activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in mania ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for further anaesthesia
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: reductions in pain interference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reductions in psychological distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Child behavior scores in the clinical range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ECBI-P score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-month ODI
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of days with NDMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Irritancy response to treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Procollagen type I N-terminal propeptide decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Osteocalcin decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total hip bone density change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Inspiratory Flow (PIF) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perioperative cardiopulmonary complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Bishop's score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of oxytocin
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Daily nosebleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum ferritin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention of serotype-specific IgG concentrations ≥ 0.35 µg/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Post-Traumatic Stress Reaction (PTSR)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Thiamine status improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-h UAE excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 24-h KIM-1 excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Prevalence of unprotected sex with HIV-negative or unknown status partner
Endpoint domain: Life impact
Endpoint subdomain: Risk behavior
Primary endpoint: T1 hypointense lesion volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: normalized low-frequency component of heart rate variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: systolic blood pressure fall during orthostatic stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of orthodontic treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of mycophenolic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Full alertness regain time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean arterial blood pressure change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Understanding of strabismus surgery
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean compliance with patching treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of total AF attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Palpebral reflex loss time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AAI threshold time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate hypersensitivity response
Endpoint domain: Adverse events/effects
Primary endpoint: Peak flows
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Blood pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: unstimulated salivary flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stimulated salivary flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rose bengal score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vulvar itching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vulvar dryness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: superficial dyspareunia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity during intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores of perceived effectiveness of dietary advice
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence to dietary changes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cmax of pinocembrin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (0,∞) of pinocembrin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dietary quality indexed by fruit and vegetable intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of calories consumed as fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rhinoconjunctivitis Quality of Life Questionnaire overall score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total 5 Symptoms Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medical Outcomes Survey Short Form 36 summary scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life